Filing Flows

Filing Flows › Evommune (EVMN) › Who owns the stock

Who owns Evommune (EVMN) stock

100 funds reported Evommune (EVMN) shares in their latest 13F filings, worth $477M in all. The largest holder is EQT Fund Management S.a r.l. ($70.3M). Last quarter 64 funds added to their stakes and 28 cut them.

Largest holders of EVMN (13F)Largest holders of EVMN (13F)EQT Fund Management S.a r.l.$70.3MRA Capital Management, L.P.$46.4MSymBiosis Capital Partners, LLC$29.4MPrice T Rowe Associates$25.8MPivotal bioVenture Partners Inves…$25.6MJanus Henderson Group$20.6MRTW Investments, LP$20.0MNan Fung Group Holdings$19.2MPoint72 Asset Management, L.P.$19.1MEventide Asset Management, LLC$16.1M

Largest holders (13F)

FundSharesValueChangeQuarter
EQT Fund Management S.a r.l.5,288,313$70.3Mincrease2026-06-30
RA Capital Management, L.P.3,494,638$46.4Munchanged2026-06-30
SymBiosis Capital Partners, LLC1,280,778$29.4Munchanged2026-03-31
Price T Rowe Associates1,940,939$25.8Mincrease2026-06-30
Pivotal bioVenture Partners Investment Advisor LLC1,926,943$25.6Munchanged2026-06-30
Janus Henderson Group896,700$20.6Mnew2026-03-31
RTW Investments, LP1,502,235$20.0Munchanged2026-06-30
Nan Fung Group Holdings1,441,032$19.2Munchanged2026-06-30
Point72 Asset Management, L.P.1,435,049$19.1Mincrease2026-06-30
Eventide Asset Management, LLC1,209,129$16.1Munchanged2026-06-30
Vestal Point Capital, LP1,000,000$13.3Mnew2026-06-30
Jupiter Topco LLC896,700$11.9Mbase2026-06-30
BlackRock886,538$11.8Mincrease2026-06-30
Vanguard Capital Management LLC881,895$11.7Mincrease2026-06-30
Baker Bros. Advisors LP847,390$11.3Munchanged2026-06-30

Evommune's latest quarter

Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most EVMN stock?

By the latest 13F filings: EQT Fund Management S.a r.l. ($70.3M); RA Capital Management, L.P. ($46.4M); SymBiosis Capital Partners, LLC ($29.4M); Price T Rowe Associates ($25.8M); Pivotal bioVenture Partners Investment Advisor LLC ($25.6M).

What is the short interest in EVMN?

3,533,042 shares were sold short at the 2026-10-15 settlement, 22.15% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.